Lysogene has named Stéphane Durant des Aulnois, from Ipsen, as new Chief Financial Officar, who will also be a member of the Executive Committee.
PARIS–(BUSINESS WIRE)–Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the appointment of Stéphane Durant des Aulnois as Chief Financial Officer. In this position, Stéphane will supervise all financial activities, as well as Alliance Management and Business Development initiatives. Stéphane will be a member of the Executive Committee.
“We are delighted to welcome Stéphane Durant des Aulnois to our expanding team. Stéphane will bring his combined experience of financial markets and operations to help us structure the company as it enters a key development phase,” said Karen Aiach, Founder, Chairman and Chief Executive Officer.
Prior to joining Lysogene, Stéphane Durant des Aulnois spent close to 9 years at Ipsen, first as Vice-President Head of Investor Relations for the Group, then as CFO of Ipsen Iberia, in charge of all financial, procurement and supply chain activities. Prior to Ipsen, Stéphane worked at LaSalle Investment management within the Acquisitions Team and at Calyon Americas within the Credit Risk Management team.
Stéphane graduated both from Paris Dauphine University and the London School of Economics, and holds an Executive Leadership diploma from Harvard Business School.